Study #2022-0621
Cohort C: Open-label phase 2, randomized, controlled multicenter study comparing Niraparib versus Platinum-Taxane doublet chemotherapy as neoadjuvant treatment in participants with homologous recombination-deficient stage III/IV ovarian cancer.
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.